CD11c/Integrin Alpha X/ITGAX Drug Discovery Landscape & Assay Solutions
- By admin
- 17 Sep 2026
- Comments
Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Myeloid-Targeting Immunotherapy and DC-Vaccine Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD11c/ITGAX drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD11c (ITGAX) & CD18 (ITGB2) Recombinant Heterodimer Protein HEK293 expressed for native glycosylation. High purity (>95%), Endotoxin controlled. Sequence Verified. |
View ITGAX Products |
| Gene Delivery | CD11c (ITGAX) Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and functional adhesion assays. |
View ITGAX Products |
| Benchmark Ab | Anti-CD11c Recombinant Reference Antibody Recombinant positive control derived from benchmark clones (e.g., Clone 3.9 sequence). |
View ITGAX Products |
| Validator | ITGAX siRNA Set Target-specific knockdown verification in primary dendritic cells or macrophages. |
View ITGAX Products |
| Related Target A | ITGB2 (CD18) The essential beta-2 integrin subunit required to form functional CR4 heterodimers with CD11c. |
View ITGB2 Products |
| Related Target B | LY75 (DEC-205) Synergistic endocytic receptor on dendritic cells, highly utilized in antigen-delivery vaccine strategies. |
View LY75 Products |
| Related Target C | CLEC9A Dendritic cell-specific receptor co-targeted with CD11c to optimize antigen cross-presentation. |
View CLEC9A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformation-dependent binding (integrin heterodimerization requirement) | Co-expressed CD11c/CD18 heterodimers from HEK293, ensuring correct folding and native glycosylation. |
| Cross-species ortholog screening (Human vs. Mouse/Cyno) | Sequence-verified Human, Mouse, and Cynomolgus CD11c recombinant proteins with high purity (>95%). |
| Lack of functional positive controls | Recombinant benchmark antibodies (biosimilars) included for assay validation. |
| False positives in binding assays | Sequence-verified negative controls and validated siRNA sets included for target specificity verification. |
Live CD11c/ITGAX R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD11c therapeutics is intensifying, with major players shifting focus from traditional cell-marker diagnostics to dendritic cell (DC)-targeted cancer vaccines and myeloid-modulating bispecifics. As first-generation immunotherapies reach the clinic, the next wave of R&D is targeting CD11c to deliver tumor antigens directly to antigen-presenting cells (APCs) in vivo, bypassing the need for complex ex vivo DC culturing.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antigen-Ab Conjugates (DC Vaccines) | Academic Consortia, Biotech Startups | Solid Tumors, Melanoma | Internalization Assay (Requires high-purity CD11c/CD18 heterodimer and pH-sensitive validation) |
| Bispecific Antibodies (Myeloid Engagers) | Roche, Amgen, Innate Pharma | Hematological Malignancies, Hairy Cell Leukemia | Bridging & Adhesion Validation (Requires lentivirus-transduced stable cell lines expressing intact CD11c/CD18) |
| mRNA Vaccine Delivery (LNP-Targeting) | BioNTech, Moderna | Infectious Diseases, Oncology | Targeting Specificity Assay (Requires recombinant CD11c vs. CD11b/CD11a counter-screening panels) |